Semaglutide vs Tirzepatide Cardiovascular Outcomes Head-to-Head in T2D Patients | Research

The takeaway

Comparative cardiovascular outcomes of semaglutide versus tirzepatide in T2D patients were evaluated, providing the first head-to-head cardiovascular data for these two blockbuster GLP-1 drugs.

Head-to-head at last
The first direct cardiovascular comparison between semaglutide and tirzepatide — answering whether dual GIP/GLP-1 beats GLP-1 alone for the heart

What the researchers found

Head-to-head cardiovascular outcome comparison of semaglutide vs tirzepatide in T2D patients, providing the first comparative CV data for these two leading incretin drugs.

Why it matters

Billions of dollars and millions of patients depend on whether tirzepatide's dual mechanism provides extra heart protection over semaglutide.

How the study worked

Study comparing cardiovascular outcomes between semaglutide and tirzepatide in T2D patients.

What this study cannot tell us

Study details in full paper.

How to read the evidence

Head-to-head cardiovascular comparison.

When this study was published

Published in 2025.

The bigger picture

The semaglutide-tirzepatide comparison is the most important drug comparison in metabolic medicine today.

Questions still open

Does tirzepatide's GIP co-agonism add cardiovascular benefit?
Should CV outcome data guide choice between these drugs?
Would triple agonists show even greater CV protection?

Common questions

Which is better for the heart: semaglutide or tirzepatide?

This study provides the first head-to-head cardiovascular comparison. The answer depends on the full results, which address whether tirzepatide's dual mechanism provides extra heart protection.

Does the extra GIP receptor in tirzepatide help the heart?

That is exactly what this study tests. GIP receptor activation may provide additional cardiovascular benefits beyond GLP-1 alone — or it may not make a meaningful difference for heart outcomes.

Read the original research

Cardiovascular outcomes of semaglutide and tirzepatide for patients with type 2 diabetes in clinical practice.

Nature medicine, 32(1), 342-352

View on PubMed ↗Publisher’s paper ↗

Citation

Krüger, Nils; Schneeweiss, Sebastian; Desai, Rishi J; Sreedhara, Sushama Kattinakere; Kehoe, Anna R; Fuse, Kenshiro; Hahn, Georg; Schunkert, Heribert; Wang, Shirley V. (2026). Cardiovascular outcomes of semaglutide and tirzepatide for patients with type 2 diabetes in clinical practice.. Nature medicine, 32(1), 342-352. https://doi.org/10.1038/s41591-025-04102-x